Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Return of the Pancreas: Evaluating Impact of CFTR Modulators on Pancreatic Function
NCT07632768Phase 4Completed
- Sponsor
- Indiana University
- Start
- Dec 2024
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in cystic fibrosis (CF) and exocrine pancreatic insufficiency (EPI), sponsored by Indiana University. Primary endpoints: Body Mass Index at 6 months, Weight at 6 months and 1 more. Started Dec 2024; status: completed.
02
Conditions
cystic fibrosis (CF)exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on NCT07632768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07632768.